{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:36:45Z","timestamp":1794875805881,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","award":["1400182"],"award-info":[{"award-number":["1400182"]}],"id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-024-03871-5","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T01:02:11Z","timestamp":1723510931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34+ cells and PD-L1 CAR-modified UCB-CD34+-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells"],"prefix":"10.1186","volume":"15","author":[{"given":"Farhoodeh","family":"Ghaedrahmati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vajihe","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooria","family":"Seyedhosseini-Ghaheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7237-1984","authenticated-orcid":false,"given":"Nafiseh","family":"Esmaeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"1","key":"3871_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"issue":"8","key":"3871_CR2","first-page":"717","volume":"41","author":"I-Y Jung","year":"2018","unstructured":"Jung I-Y, Lee J. Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies. Mol Cells. 2018;41(8):717.","journal-title":"Mol Cells"},{"issue":"1","key":"3871_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, Ozkazanc D, Kucerova L, et al. Natural killer cells in clinical development as non-engineered engineered and combination therapies. J Hematol Oncol. 2022;15(1):164.","journal-title":"J Hematol Oncol."},{"issue":"2","key":"3871_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3871_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.","journal-title":"J Hematol Oncol"},{"key":"3871_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59: 102975.","journal-title":"EBioMedicine"},{"issue":"2","key":"3871_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024;30(2):507\u201318.","journal-title":"Nat Med"},{"issue":"2","key":"3871_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cac2.12394","volume":"43","author":"F Ghaedrahmati","year":"2023","unstructured":"Ghaedrahmati F, Esmaeil N, Abbaspour M. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Commun (Lond). 2023;43(2):177\u2013213.","journal-title":"Cancer Commun (Lond)"},{"key":"3871_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"3871_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Guegan JP, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2(8):794\u2013802.","journal-title":"Nat Cancer"},{"key":"3871_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109625","volume":"121","author":"E McGowan","year":"2020","unstructured":"McGowan E, Lin Q, Ma G, Yin H, Chen S, Lin Y. PD-1 disrupted CAR-T cells in the treatment of solid tumors: promises and challenges. Biomed Pharmacother. 2020;121: 109625.","journal-title":"Biomed Pharmacother"},{"issue":"47","key":"3871_CR12","doi-asserted-by":"publisher","first-page":"eaab1187","DOI":"10.1126\/sciadv.add1187","volume":"8","author":"WN Liu","year":"2022","unstructured":"Liu WN, So WY, Harden SL, Fong SY, Wong MXY, Tan WWS, et al. Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model. Sci Adv. 2022;8(47):eaab1187.","journal-title":"Sci Adv"},{"issue":"2","key":"3871_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.stem.2018.07.007","volume":"23","author":"EL Siegler","year":"2018","unstructured":"Siegler EL, Zhu Y, Wang P, Yang L. Off-the-shelf CAR-NK cells for cancer immunotherapy. Cell Stem Cell. 2018;23(2):160\u20131.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"3871_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F, Xie S, Chen M, Li Y, Yue J, Ma J, et al. Advances in NK cell production. Cell Mol Immunol. 2022;19(4):460\u201381.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"3871_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40259-021-00494-7","volume":"35","author":"X Yao","year":"2021","unstructured":"Yao X, Matosevic S. Cryopreservation of NK and T cells without DMSO for adoptive cell-based immunotherapy. BioDrugs. 2021;35(5):529\u201345.","journal-title":"BioDrugs"},{"issue":"12","key":"3871_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12387","volume":"12","author":"F St-Denis-Bissonnette","year":"2023","unstructured":"St-Denis-Bissonnette F, Cummings SE, Qiu S, Stalker A, Muradia G, Mehic J, et al. A clinically relevant large-scale biomanufacturing workflow to produce natural killer cells and natural killer cell-derived extracellular vesicles for cancer immunotherapy. J Extracell Vesicles. 2023;12(12): e12387.","journal-title":"J Extracell Vesicles"},{"issue":"4","key":"3871_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115178","volume":"5","author":"U Koehl","year":"2016","unstructured":"Koehl U, Kalberer C, Spanholtz J, Lee D, Miller J, Cooley S, et al. Advances in clinical NK cell studies: donor selection, manufacturing and quality control. Oncoimmunology. 2016;5(4): e1115178.","journal-title":"Oncoimmunology"},{"key":"3871_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3389\/fimmu.2017.00676","volume":"8","author":"J Wagner","year":"2017","unstructured":"Wagner J, Pfannenstiel V, Waldmann A, Bergs JW, Brill B, Huenecke S, et al. A two-phase expansion protocol combining interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against rhabdomyosarcoma. Front Immunol. 2017;8:676.","journal-title":"Front Immunol"},{"issue":"7","key":"3871_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/sctm.20-0459","volume":"10","author":"J Arias","year":"2021","unstructured":"Arias J, Yu J, Varshney M, Inzunza J, Nalvarte I. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions. Stem Cells Transl Med. 2021;10(7):987\u201395.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"3871_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13287-023-03461-x","volume":"14","author":"W Wen","year":"2023","unstructured":"Wen W, Chen X, Shen XY, Li HY, Zhang F, Fang FQ, et al. Enhancing cord blood stem cell-derived NK cell growth and differentiation through hyperosmosis. Stem Cell Res Ther. 2023;14(1):295.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"3871_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.13197","volume":"315","author":"S Sun","year":"2023","unstructured":"Sun S, Wijanarko K, Liani O, Strumila K, Ng ES, Elefanty AG, et al. Lymphoid cell development from fetal hematopoietic progenitors and human pluripotent stem cells. Immunol Rev. 2023;315(1):154\u201370.","journal-title":"Immunol Rev"},{"issue":"6","key":"3871_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MOH.0000000000000732","volume":"29","author":"PA Shi","year":"2022","unstructured":"Shi PA, Luchsinger LL, Greally JM, Delaney CS. Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications. Curr Opin Hematol. 2022;29(6):317\u201326.","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"3871_CR23","doi-asserted-by":"publisher","first-page":"e008435","DOI":"10.1136\/jitc-2023-008435","volume":"12","author":"N Poirier","year":"2024","unstructured":"Poirier N, Paquin V, Leclerc S, Lisi V, Marmolejo C, Affia H, et al. Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings. J Immunother Cancer. 2024;12(5):e008435.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3871_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.devcel.2020.02.016","volume":"53","author":"C Dege","year":"2020","unstructured":"Dege C, Fegan KH, Creamer JP, Berrien-Elliott MM, Luff SA, Kim D, et al. Potently cytotoxic natural killer cells initially emerge from erythro-myeloid progenitors during mammalian development. Dev Cell. 2020;53(2):229-39 e7.","journal-title":"Dev Cell"},{"key":"3871_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cytogfr.2018.03.008","volume":"42","author":"H Stabile","year":"2018","unstructured":"Stabile H, Fionda C, Santoni A, Gismondi A. Impact of bone marrow-derived signals on NK cell development and functional maturation. Cytokine Growth Factor Rev. 2018;42:13\u20139.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"3871_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274\u201383.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"3871_CR27","first-page":"1770","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang L, Liu M, Yang S, Wang J, Feng X, Han Z. Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance. Am J Cancer Res. 2021;11(4):1770\u201391.","journal-title":"Am J Cancer Res"},{"key":"3871_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","volume":"2048","author":"H Zhu","year":"2019","unstructured":"Zhu H, Kaufman DS. An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells. Methods Mol Biol. 2019;2048:107\u201319.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"3871_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.stem.2013.08.012","volume":"13","author":"C Boiers","year":"2013","unstructured":"Boiers C, Carrelha J, Lutteropp M, Luc S, Green JC, Azzoni E, et al. Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells. Cell Stem Cell. 2013;13(5):535\u201348.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"3871_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2022.103452","volume":"61","author":"A Rafat","year":"2022","unstructured":"Rafat A, Dizaji Asl K, Mazloumi Z, Samadirad B, Ashrafianbonab F, Farahzadi R, et al. Bone marrow CD34 positive cells may be suitable for collection after death. Transfus Apher Sci. 2022;61(6): 103452.","journal-title":"Transfus Apher Sci"},{"key":"3871_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120402","volume":"295","author":"A Rafat","year":"2022","unstructured":"Rafat A, Dizaji Asl K, Mazloumi Z, Movassaghpour AA, Talebi M, Shanehbandi D, et al. Telomerase inhibition on acute myeloid leukemia stem cell induced apoptosis with both intrinsic and extrinsic pathways. Life Sci. 2022;295: 120402.","journal-title":"Life Sci"},{"key":"3871_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101797","volume":"77","author":"R Farahzadi","year":"2023","unstructured":"Farahzadi R, Valipour B, Anakok OF, Fathi E, Montazersaheb S. The effects of encapsulation on NK cell differentiation potency of C-kit+ hematopoietic stem cells via identifying cytokine profiles. Transpl Immunol. 2023;77: 101797.","journal-title":"Transpl Immunol"},{"issue":"4","key":"3871_CR33","first-page":"264","volume":"22","author":"E Fathi","year":"2021","unstructured":"Fathi E, Kholosi Pashutan M, Farahzadi R, Nozad CH. L-carnitine in a certain concentration increases expression of cell surface marker CD34 and apoptosis in the rat bone marrow CD34(+) hematopoietic stem cells. Iran J Vet Res. 2021;22(4):264\u201371.","journal-title":"Iran J Vet Res"},{"issue":"52","key":"3871_CR34","doi-asserted-by":"publisher","first-page":"90215","DOI":"10.18632\/oncotarget.21652","volume":"8","author":"F Zhang","year":"2017","unstructured":"Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, et al. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget. 2017;8(52):90215.","journal-title":"Oncotarget"},{"issue":"9","key":"3871_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"11","key":"3871_CR36","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3390\/cancers11111756","volume":"11","author":"K Marhelava","year":"2019","unstructured":"Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R. Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers. 2019;11(11):1756.","journal-title":"Cancers"},{"issue":"12","key":"3871_CR37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/carcin\/bgad072","volume":"44","author":"Z Jiao","year":"2023","unstructured":"Jiao Z, Zhang J. Interplay between inflammasomes and PD-1\/PD-L1 and their implications in cancer immunotherapy. Carcinogenesis. 2023;44(12):795\u2013808.","journal-title":"Carcinogenesis"},{"issue":"5","key":"3871_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.14348\/molcells.2021.0044","volume":"44","author":"YJ Lee","year":"2021","unstructured":"Lee YJ, Lee JB, Ha S-J, Kim HR. Clinical perspectives to overcome acquired resistance to anti\u2013programmed death-1 and anti\u2013programmed death ligand-1 therapy in non-small cell lung cancer. Mol Cells. 2021;44(5):363.","journal-title":"Mol Cells"},{"issue":"11","key":"3871_CR39","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jcyt.2015.07.011","volume":"17","author":"A Perez-Martinez","year":"2015","unstructured":"Perez-Martinez A, Fernandez L, Valentin J, Martinez-Romera I, Corral MD, Ramirez M, et al. A phase I\/II trial of interleukin-15\u2013stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy. 2015;17(11):1594\u2013603.","journal-title":"Cytotherapy"},{"issue":"24","key":"3871_CR40","doi-asserted-by":"publisher","first-page":"10961","DOI":"10.1073\/pnas.1005641107","volume":"107","author":"M Cella","year":"2010","unstructured":"Cella M, Otero K, Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci U S A. 2010;107(24):10961\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3871_CR41","doi-asserted-by":"publisher","first-page":"11075","DOI":"10.1038\/s41598-017-09259-1","volume":"7","author":"HR Lee","year":"2017","unstructured":"Lee HR, Son CH, Koh EK, Bae JH, Kang CD, Yang K, et al. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Sci Rep. 2017;7(1):11075.","journal-title":"Sci Rep"},{"issue":"9","key":"3871_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/imcb.12679","volume":"101","author":"LJ Dobson","year":"2023","unstructured":"Dobson LJ, Saunderson SC, Smith-Bell SW, McLellan AD. Sleeping Beauty kit sets provide rapid and accessible generation of artificial antigen-presenting cells for natural killer cell expansion. Immunol Cell Biol. 2023;101(9):847\u201356.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"3871_CR43","doi-asserted-by":"publisher","first-page":"e002500","DOI":"10.1136\/jitc-2021-002500","volume":"10","author":"M Bajor","year":"2022","unstructured":"Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A, et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. 2022;10(1):e002500.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3871_CR44","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"2","key":"3871_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.humimm.2020.12.002","volume":"82","author":"G Liu","year":"2021","unstructured":"Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, et al. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Hum Immunol. 2021;82(2):130\u20138.","journal-title":"Hum Immunol"},{"issue":"10","key":"3871_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1154","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H, et al. Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. Clin Transl Immunology. 2020;9(10): e1154.","journal-title":"Clin Transl Immunology"},{"key":"3871_CR47","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3389\/fimmu.2018.01104","volume":"9","author":"P Kosti","year":"2018","unstructured":"Kosti P, Maher J, Arnold JN. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol. 2018;9:1104.","journal-title":"Front Immunol"},{"issue":"1","key":"3871_CR48","doi-asserted-by":"publisher","first-page":"e000450","DOI":"10.1136\/jitc-2019-000450","volume":"8","author":"KP Fabian","year":"2020","unstructured":"Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020;8(1):e000450.","journal-title":"J Immunother Cancer"},{"key":"3871_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-020-00198-0","volume":"8","author":"L Qin","year":"2020","unstructured":"Qin L, Zhao R, Chen D, Wei X, Wu Q, Long Y, et al. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomark Res. 2020;8:19.","journal-title":"Biomark Res"},{"key":"3871_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","volume":"430","author":"BKR Chaganty","year":"2018","unstructured":"Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion. Cancer Lett. 2018;430:47\u201356.","journal-title":"Cancer Lett"},{"issue":"20","key":"3871_CR51","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.3390\/cancers14205115","volume":"14","author":"S Vivekanandhan","year":"2022","unstructured":"Vivekanandhan S, Knutson KL. Resistance to Trastuzumab. Cancers (Basel). 2022;14(20):5115.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"3871_CR52","first-page":"11","volume":"12","author":"S Mohammadzadeh","year":"2023","unstructured":"Mohammadzadeh S, Andalib A, Khanahmad H, Esmaeil N. Human recombinant soluble PD1 can interference in T cells and Treg cells function in response to MDA-MB-231 cancer cell line. Am J Clin Exp Immunol. 2023;12(2):11\u201323.","journal-title":"Am J Clin Exp Immunol"},{"issue":"4","key":"3871_CR53","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.3390\/ijms24044197","volume":"24","author":"K Cheng","year":"2023","unstructured":"Cheng K, Feng X, Chai Z, Wang Z, Liu Z, Yan Z, et al. 4\u20131BB-based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody. Int J Mol Sci. 2023;24(4):4197.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3871_CR54","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","volume":"139","author":"EA Chong","year":"2022","unstructured":"Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139(7):1026\u201338.","journal-title":"Blood"},{"issue":"8","key":"3871_CR55","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130\u201344.","journal-title":"J Clin Invest"},{"issue":"1","key":"3871_CR56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-024-06438-7","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang B, Yang M, Zhang W, Liu N, Wang D, Jing L, et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. Cell Death Dis. 2024;15(1):50.","journal-title":"Cell Death Dis"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-03871-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-024-03871-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-03871-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:13:53Z","timestamp":1723554833000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-024-03871-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3871"],"URL":"https:\/\/doi.org\/10.1186\/s13287-024-03871-5","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research project entitled\u201d Design and construction of chimeric antigen receptor targeting PD-L1 and its expression in human umbilical cord blood stem cells-derived natural killer cells\u201d was approved by the Research Ethics Committees of Isfahan University of Medical Sciences and Health Services Ethics Committee of the Isfahan University of Medical Sciences (code: IR.MUI.REC.1400.050) on 2021-09-29. All participants provided informed consent before enrollment in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors hereby provide consent for the publication of the manuscript detailed above.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}